Close Menu

CHICAGO (GenomeWeb) – Cancer informatics and precision medicine company Tempus said today that it has landed $200 million in a Series F investment round. This new round brings the four-year-old firm's total venture capital to $520 million and valuation to $3.1 billion.

Series F investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth, and T. Rowe Price. With the investment, Novo Holdings Director Robert Ghenchev has joined the Tempus board of directors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.